January 4, 2016
A team of researchers, with the aid of the Gordon supercomputer at the San Diego Supercomputer Center based at UC San Diego, has identified a class of possible antibiotics with the potential to disable previously drug-resistant bacteria.
December 5, 2013
…therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
June 15, 2017
University of California San Diego School of Medicine has entered a five-year strategic partnership with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover meaningful treatments for metabolic diseases.
May 22, 2023
The latest space experiments from UC San Diego and Axiom Space will explore therapies for breast and colorectal cancer aboard the ISS, and monitor astronauts’ stem cell health over time.
September 5, 2018
…support to weather risky early-stage processes and expedite the drug-development cycle, allowing patients to receive treatment faster.
January 31, 2023
In the span of just a few weeks, Don Cleveland, a leading researcher in the study of neurodegenerative diseases like ALS and Alzheimer’s, has received three major awards.
September 16, 2013
Biologists at the University of California, San Diego have developed a revolutionary new method for identifying and characterizing antibiotics, an advance that could lead to the discovery of new antibiotics to treat antibiotic resistant bacteria.
April 26, 2021
Researchers have created to novel biobanks of diverse tissues from animals to further explore the biological bases and consequences of addiction to cocaine and oxycodone.
May 16, 2011
…at the forefront of discovery. The Office of Research Affairs serves all of those groups, and we see our role as boosting their effectiveness and ensuring their success. Why has research flourished at UC San Diego despite the economic recession? VC Brown: Departments, laboratories and other units across campus are…
October 26, 2022
Researchers at UC San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the possibility of new therapies, including for multiple forms of cancer.
